Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03882845 · 1 trial · 1 indication
Post dose is measured at 24, 48 and 96 hours after dose.
| Arm | Type | Description |
|---|---|---|
| Suspension/fasted | EXPERIMENTAL | - |
| Tablet/fasted | EXPERIMENTAL | - |
| Tablet/fed | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-03882845 | DRUG | 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years,Females must be of non-childbearing potential. Body mass index of 17.5 to 30.5 kg/m2. * Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other st...
PF-03882845 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for type 2 diabetes mellitus. It is a Phase 1 candidate in the metabolic therapeutic area and has been studied in a single completed clinical trial. It is not an approved medicine.
PF-03882845 targets NR3C2 and acts as an antagonist at that receptor. NR3C2 is also known as the mineralocorticoid receptor. Antagonism of this target is the mechanism under investigation for type 2 diabetes mellitus in the Phase 1 program.
Pfizer, Inc. (ticker PFE) is the developer of PF-03882845. The company sponsored the Phase 1 trial of the compound in type 2 diabetes mellitus. Pfizer holds the development program for this small molecule asset.
PF-03882845 is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active. The program enrolled 12 participants in total.
PF-03882845 has been studied in one completed Phase 1 trial, NCT01366287. That trial examined absorption of PF-03882845 in healthy volunteers receiving oral tablet versus suspension formulations and the effect of food on absorption. It enrolled 12 participants in Belgium and is no longer active.